{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:17:08Z","timestamp":1785838628529,"version":"3.56.0"},"reference-count":21,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The long-term safety and efficacy of leuprolide acetate (LA) intramuscular (IM) depot in children with central precocious puberty (CPP) have not been examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We evaluated the 144-week efficacy and safety of LA IM depot with 6-month dosing frequency for the treatment of CPP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Children with CPP received 45\u2005mg LA IM depot in a phase 3, single-arm study (NCT03695237) that enrolled both treatment-naive (n = 27) and previously treated (n = 18) children (age: 7.8 \u00b1 1.27 years). Outcomes included suppression of peak-stimulated LH (&amp;lt;4\u2005mIU\/mL), basal estradiol (&amp;lt;20\u2005pg\/mL), and testosterone (&amp;lt;30\u2005ng\/dL) and physical puberty signs (based on nonmissing data), height-related outcomes, patient\/parent-reported outcomes, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Peak-stimulated LH was suppressed in 93%, 95%, 100%, and 100% of children at weeks 72, 96, 120, and 144, respectively; basal sex hormones were suppressed in all children. Most children had pubertal signs suppressed during long-term treatment (Tanner staging, weeks 72-144, girls: 86.4-94.9%; boys, 50.0-75.0%). After week 48, mean incremental height velocity remained relatively stable, and mean ratio of bone age to chronological age was 1.2. At week 144, mean annualized change from baseline in predicted adult height (PAH) was 1.4\u2005cm\/year, and mean absolute PAH in girls improved compared with mid-parental height. Health-related quality of life was maintained. No new related safety concerns were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Six-month LA IM depot for 144 weeks demonstrated a sustained inhibition of the GnRH axis in children with CPP with an acceptable safety profile. Health-related quality of life was maintained, and PAH improved during \u223c3 years of treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvaf224","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:43:58Z","timestamp":1769690638000},"source":"Crossref","is-referenced-by-count":1,"title":["Long-term Safety, Efficacy, and PROs: Phase 3 Study of Leuprolide Acetate 6-month IM Depot in Central Precocious Puberty"],"prefix":"10.1210","volume":"10","author":[{"given":"Karen O","family":"Klein","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of California San Diego School of Medicine and Rady Children's Hospital , San Diego, CA 92123 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1175-3852","authenticated-orcid":false,"given":"Nelly","family":"Mauras","sequence":"additional","affiliation":[{"name":"Nemours Children's Health , Jacksonville, FL 32207 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Nayak","sequence":"additional","affiliation":[{"name":"Pediatric Endocrine Associates, Greenwood Village, CO 80111 ,","place":["USA"]},{"name":"University of Colorado School of Medicine , Aurora, CO 80045 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1105-7056","authenticated-orcid":false,"given":"Bhuvana","family":"Sunil","sequence":"additional","affiliation":[{"name":"Mary Bridge Children's Hospital , Tacoma, WA 98403 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M","family":"Soliman","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL 60064 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0811-622X","authenticated-orcid":false,"given":"Alvina R","family":"Kansra","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL 60064 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"issue":"10","key":"2026013003345818000_bvaf224-B1","doi-asserted-by":"crossref","first-page":"e3660","DOI":"10.1210\/clinem\/dgaa479","article-title":"Phase 3 trial of a small-volume subcutaneous 6-month duration leuprolide acetate treatment for central precocious puberty","volume":"105","author":"Klein","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026013003345818000_bvaf224-B2","doi-asserted-by":"crossref","first-page":"bvad071","DOI":"10.1210\/jendso\/bvad071","article-title":"Efficacy and safety of leuprolide acetate 6-month depot for the treatment of central precocious puberty: a phase 3 study","volume":"7","author":"Klein","year":"2023","journal-title":"J Endocr Soc"},{"issue":"1","key":"2026013003345818000_bvaf224-B3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1687-9856-2011-7","article-title":"Efficacy of leuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study","volume":"2011","author":"Lee","year":"2011","journal-title":"Int J Pediatr Endocrinol"},{"issue":"Suppl. 1","key":"2026013003345818000_bvaf224-B4","first-page":"116","article-title":"24 months treatment experience of two leuprolide acetate 3 month depot formulations for children with central precocious puberty (ESPE abstract P1-D3-367)","volume":"78","author":"Lee","year":"2012","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"2026013003345818000_bvaf224-B5","doi-asserted-by":"crossref","first-page":"398639","DOI":"10.1186\/1687-9856-2010-398639","article-title":"Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery","volume":"2010","author":"Neely","year":"2010","journal-title":"Int J Pediatr Endocrinol"},{"issue":"3","key":"2026013003345818000_bvaf224-B6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1515\/jpem-2020-0471","article-title":"Gonadotropin releasing hormone analogue therapy in girls with idiopathic precocious puberty\/early-fast puberty: dynamics in adiposity indices, eating habits and quality of life","volume":"34","author":"Loochi","year":"2021","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"Suppl. 1","key":"2026013003345818000_bvaf224-B7","first-page":"1","article-title":"The effect of GnRH-analogue therapy on the quality of life of patients with central precocious puberty and their families (ESPE abstract P-P2-307)","volume":"89","author":"Lucaccioni","year":"2018","journal-title":"Horm Res Paediatr"},{"key":"2026013003345818000_bvaf224-B8","author":"AbbVie Inc"},{"key":"2026013003345818000_bvaf224-B9","author":"AbbVie Inc"},{"issue":"Suppl.","key":"2026013003345818000_bvaf224-B10","first-page":"791","article-title":"Precocious puberty and body composition: effects of GnRH analog treatment","volume":"13","author":"Chiumello","year":"2000","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2026013003345818000_bvaf224-B11","volume-title":"Assessing the Skeletal Maturity of the Hand-Wrist: FELS Method","author":"Roche","year":"1988"},{"issue":"1","key":"2026013003345818000_bvaf224-B12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1109\/TMI.2008.926067","article-title":"The BoneXpert method for automated determination of skeletal maturity","volume":"28","author":"Thodberg","year":"2009","journal-title":"IEEE Trans Med Imaging"},{"issue":"4","key":"2026013003345818000_bvaf224-B13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0022-3476(52)80205-7","article-title":"Tables for predicting adult height from skeletal age: revised for use with the greulich-pyle hand standards","volume":"40","author":"Bayley","year":"1952","journal-title":"J Pediatr"},{"key":"2026013003345818000_bvaf224-B14","author":"Varni"},{"issue":"1","key":"2026013003345818000_bvaf224-B15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1477-7525-5-2","article-title":"Parent proxy-report of their children's health-related quality of life: an analysis of 13,878 parents\u2019 reliability and validity across age subgroups using the PedsQL 4.0 Generic Core Scales","volume":"5","author":"Varni","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"2026013003345818000_bvaf224-B16","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/jpepsy\/jsy038","article-title":"PROMIS peer relationships short form: how well does self-report correlate with data from peers?","volume":"43","author":"Devine","year":"2018","journal-title":"J Pediatr Psychol"},{"key":"2026013003345818000_bvaf224-B17","author":"HealthMeasures"},{"issue":"9","key":"2026013003345818000_bvaf224-B18","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1210\/jc.2013-4471","article-title":"36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty","volume":"99","author":"Lee","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026013003345818000_bvaf224-B19","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1210\/jc.2011-2704","article-title":"Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty","volume":"97","author":"Lee","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026013003345818000_bvaf224-B20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/03007995.2019.1699517","article-title":"A survey of care pathway and health-related quality of life impact for children with central precocious puberty","volume":"36","author":"Klein","year":"2020","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2026013003345818000_bvaf224-B21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1515\/jpem-2022-0476","article-title":"Using change in predicted adult height during GnRH agonist treatment for individualized treatment decisions in girls with central precocious puberty","volume":"36","author":"Trujillo","year":"2023","journal-title":"J Pediatr Endocrinol Metab"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/2\/bvaf224\/66638924\/bvaf224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/2\/bvaf224\/66638924\/bvaf224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:35:04Z","timestamp":1769762104000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaf224\/8445231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,7]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaf224","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,7]]},"article-number":"bvaf224"}}